LivaNova - Page title

LivaNova PLC: Miscellaneous

Aug 5, 2016

5 August 2016

Miscellaneous

LivaNova PLC (the “Company” or “LivaNova”) today announced that it filed a Quarterly Report on Form 10-Q under the U.S. Securities Exchange Act of 1934, as amended, for the six months ended 30 June 2016 (“Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”) on 5 August 2016.

The Form 10-Q can be found on the SEC’s website at www.sec.gov and in the Investor Relations section of the Company’s website at www.livanova.com. A copy of the Form 10-Q has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at http://www.morningstar.co.uk/uk/NSM.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:

Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com